Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2014; 20(10): 2595-2605
Published online Mar 14, 2014. doi: 10.3748/wjg.v20.i10.2595
Table 1 Thrombopoietin-receptor agonists for the treatment of thrombocytopenia
AgentTarget diseaseDose (route)
Recombinant human thrombopoietin
rhTPOWithdrawn from clinical use(intravenous)
PEG-rHuMGDFWithdrawn from clinical use(subcutaneous)
rhIL-11Chemotherapy-induced TCP[40,42]50 μg/kg per day (subcutaneous)
TCP in patients with cirrhosis[43]50 μg/kg per day (subcutaneous)
TPO mimetrics (peptide TPO receptor agonists and nonpeptide TPO receptor agonists)
RomiplostimITP[47-50]0.2-10 μg/kg once a week (subcutaneous)
Myelodysplastic syndrome[51-53]Once a week (subcutaneous)
HCV-related TCP[54,97]2 μg/kg once a week (subcutaneous)
EltrombopagITP[55,56]50 mg once daily (oral)
HCV-related TCP25 mg once daily (oral)
E5501HCV-related TCP (phase II; NCT00914927)
Table 2 Approaches to treat thrombocytopenia induced by liver cirrhosis based on preoperative splenic volume[62]
Splenic volumeSV < 400 mL400 mLSV700 mL700 mL< SV
ProcedureL-splenectomyL-splenectomyL-splenectomy
oror
Single PSERepeated PSE
Target in PSEInfarcted splenic areaNon-infarcted splenic area
(infarcted splenic volume)(infarcted splenic ratio and non-infarcted splenic volume)
Table 3 Comparison between partial splenic embolization and laparoscopic splenectomy for thrombocytopenia caused by liver cirrhosis
ProcedurePSEL-splenectomy (HALS)
Invasiveness++++
(no transfusion)(rarely with major bleeding)
(local anesthesia)(general anesthesia)
Platelet increase+++++
Specific complicationSplenic abscessPortal thrombosis, OPSI
Available in case with HCCSynchronous TACESynchronous RFA or hepatectomy